Serological biomarkers of joint tissue turnover predict tocilizumab response at baseline

J Clin Rheumatol. 2014 Sep;20(6):332-5. doi: 10.1097/RHU.0000000000000150.
No abstract available

Publication types

  • Clinical Trial, Phase III

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / immunology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Arthritis, Rheumatoid / blood
  • Arthritis, Rheumatoid / drug therapy*
  • Biomarkers / blood
  • Connective Tissue / metabolism*
  • Decision Trees
  • Extracellular Matrix Proteins / blood*
  • Female
  • Follow-Up Studies
  • Humans
  • Joints / metabolism*
  • Male
  • Middle Aged
  • Receptors, Interleukin-6 / immunology
  • Risk Assessment
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • Extracellular Matrix Proteins
  • Receptors, Interleukin-6
  • tocilizumab